News Arbutus Presents New Data on AB-729, AB-836 and AB-101 at the EASL International Liver Congress™ 2022 and Provides AB-836 Clinical Update Continue Reading Previous Immunocore announces the presentation of initial data from the Phase 1 ImmTAV® trial for chronic Hepatitis B at the EASL International Liver Congress™Next Vir Biotechnology Announces New Clinical Data From its Broad Hepatitis B Program Related Stories News Philippine Tourism Has Three Arrival Counters and a 300,000 Gap News CIMC Group Announces Results for the First Three Quarters of 2026 News U.S. Polo Assn. Executes Early on Europe’s Digital Product Passport Mandate News COSCO SHIPPING Ports Announces 2026 Third Quarter Results News Beyond the Hype: Singapore’s Aivo Asia Scales Unified SaaS Platform to Drive Real Business Growth Through Conversational AI News Quality Containers Expands Into Tampa Bay, Following Nationwide Growth
